CL2021000636A1 - Vacuna contra el virus de la peste porcina africana - Google Patents

Vacuna contra el virus de la peste porcina africana

Info

Publication number
CL2021000636A1
CL2021000636A1 CL2021000636A CL2021000636A CL2021000636A1 CL 2021000636 A1 CL2021000636 A1 CL 2021000636A1 CL 2021000636 A CL2021000636 A CL 2021000636A CL 2021000636 A CL2021000636 A CL 2021000636A CL 2021000636 A1 CL2021000636 A1 CL 2021000636A1
Authority
CL
Chile
Prior art keywords
fever virus
swine fever
african swine
viral particle
virus vaccine
Prior art date
Application number
CL2021000636A
Other languages
English (en)
Inventor
Petrus Theodorus Johannes Willemsen
Bernardus Petrus Hubertus Peeters
Original Assignee
Stichting Wageningen Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Wageningen Res filed Critical Stichting Wageningen Res
Publication of CL2021000636A1 publication Critical patent/CL2021000636A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/187—Hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención está dirigida a una molécula de ácido nucleico recombinante que comprende un casete de expresión que codifica un poliepítopo que comprende antígenos de células T de proteínas del virus de la peste porcina africana. La invención se refiere además a una partícula viral, que comprende dicha molécula de ácido nucleico recombinante, ya una partícula viral que comprende antígenos de células B del virus de la peste porcina africana. La invención se refiere además a métodos para estimular una respuesta inmune en un cerdo que comprenden administrar la molécula recombinante de la invención, y / o la partícula viral de la invención, al cerdo en una cantidad eficaz para inducir una respuesta inmune.
CL2021000636A 2018-09-18 2021-03-16 Vacuna contra el virus de la peste porcina africana CL2021000636A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18195280 2018-09-18
CN201910239547.XA CN110904127B (zh) 2018-09-18 2019-03-27 非洲猪瘟病毒疫苗

Publications (1)

Publication Number Publication Date
CL2021000636A1 true CL2021000636A1 (es) 2021-10-01

Family

ID=63642765

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000636A CL2021000636A1 (es) 2018-09-18 2021-03-16 Vacuna contra el virus de la peste porcina africana

Country Status (15)

Country Link
US (1) US20220047694A1 (es)
EP (1) EP3852798A2 (es)
JP (1) JP7548902B2 (es)
KR (1) KR20210065128A (es)
CN (1) CN110904127B (es)
AU (1) AU2019345214A1 (es)
BR (1) BR112021005079A2 (es)
CA (1) CA3112800A1 (es)
CL (1) CL2021000636A1 (es)
CO (1) CO2021004188A2 (es)
MX (1) MX2021003175A (es)
PH (1) PH12021550580A1 (es)
TW (1) TWI777093B (es)
WO (1) WO2020060403A2 (es)
ZA (1) ZA202101615B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109810948B (zh) * 2019-01-18 2021-09-17 中国农业科学院兰州兽医研究所 抗非洲猪瘟病毒k205r蛋白单克隆抗体的杂交瘤细胞株及其分泌的抗体
WO2020193688A2 (en) 2019-03-27 2020-10-01 Boehringer Ingelheim Vetmedica Gmbh Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
CN112831597A (zh) * 2019-11-22 2021-05-25 洛阳普泰生物技术有限公司 用于非洲猪瘟病毒基因鉴别检验的实时荧光pcr扩增引物对、探针引物、及制备的试剂盒
CN111363016A (zh) * 2020-03-30 2020-07-03 中国农业大学 一种非洲猪瘟免疫抗原及其制备方法和应用
CN111393510B (zh) * 2020-04-02 2021-07-16 中国农业科学院兰州兽医研究所 一种非洲猪瘟病毒重组抗原及其应用
CN115916803A (zh) * 2020-04-14 2023-04-04 株式会社准绳生命科学 非洲猪瘟疫苗组合物
CN111575289A (zh) * 2020-05-25 2020-08-25 浙江璞题生物科技有限公司 干扰非洲猪瘟病毒基因表达的siRNA及其应用
US20230310555A1 (en) * 2020-06-30 2023-10-05 Cibus Biotechnologies, Inc. Compositions for genome editing and methods of use thereof
CN113897395B (zh) * 2020-07-06 2023-10-03 嘉兴安宇生物科技有限公司 一种非洲猪瘟的重组腺病毒疫苗及其构建方法
CN113897391B (zh) * 2020-07-06 2023-08-22 嘉兴安宇生物科技有限公司 一种非洲猪瘟的重组腺病毒疫苗及其构建方法
CN113201507B (zh) * 2020-07-10 2022-02-22 浙江海隆生物科技有限公司 一种重组的伪狂犬病病毒及其疫苗组合物
CN113896771B (zh) * 2020-08-26 2023-10-27 中国农业科学院兰州兽医研究所 一类促进猪机体产生非洲猪瘟病毒抗原特异性免疫应答的多肽及其应用
CN112472801A (zh) * 2020-12-22 2021-03-12 华南农业大学 非洲猪瘟p30、p54、p72和B602L的DNA疫苗和亚单位疫苗及其制备方法与应用
CN113308422A (zh) * 2021-07-30 2021-08-27 山东格研生物技术有限公司 一种博兹曼军团菌分离培养基及其制备方法
EP4393505A1 (en) * 2021-08-27 2024-07-03 Bioapplications Inc. Vaccine for preventing african swine fever, comprising african swine fever virus-derived antigen protein
CN114437236B (zh) * 2022-01-11 2023-06-27 中国农业科学院兰州兽医研究所 一种重组非洲猪瘟病毒多表位融合蛋白、制备及其应用
CN114940705A (zh) * 2022-05-05 2022-08-26 中国农业科学院兰州兽医研究所 非洲猪瘟病毒p30抗原表位蛋白及其制备方法和用途
CN114989266B (zh) * 2022-06-16 2024-02-13 华中农业大学 一种非洲猪瘟病毒pA104R蛋白免疫抑制相关氨基酸位点及其应用
CN115109800B (zh) * 2022-06-22 2024-05-03 吉林大学 表面展示猪传染性胃肠炎病毒s1蛋白的细菌样颗粒的制备方法
CN115806600B (zh) * 2022-09-30 2024-04-05 扬州大学 一种鸡滑液囊支原体蛋白GrpE及其制备方法、作为亚单位疫苗的应用
CN115925887B (zh) * 2022-10-27 2024-02-09 华中农业大学 非洲猪瘟病毒pA104R蛋白免疫优势性B细胞抗原表位及其单克隆抗体与应用
CN116589539B (zh) * 2023-04-10 2024-02-13 中国农业科学院兰州兽医研究所 九组分抗原非洲猪瘟亚单位疫苗
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用
CN116656731B (zh) * 2023-05-25 2024-04-12 军事科学院军事医学研究院军事兽医研究所 一种表达非洲猪瘟病毒多种蛋白的重组金丝雀痘病毒及其构建方法
CN116785419B (zh) * 2023-05-26 2024-10-22 中国农业科学院兰州兽医研究所 二十三组分抗原非洲猪瘟亚单位疫苗
CN116694583B (zh) * 2023-06-02 2024-10-22 中国农业科学院兰州兽医研究所 七组分抗原非洲猪瘟重组腺病毒疫苗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
SE0003538D0 (sv) 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
WO2009008888A1 (en) 2007-07-10 2009-01-15 Matthias Rath African swine virus polypeptides as vaccines and its therapeutic use thereof
EP2168987A1 (en) 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
WO2011110953A2 (en) * 2010-03-09 2011-09-15 Artemev, Timur Polyepitope constructs and methods for their preparation and use
CN101825633B (zh) * 2010-04-23 2013-01-30 天津出入境检验检疫局动植物与食品检测中心 用于检测非洲猪瘟病毒的竞争elisa试剂盒
CN101991848B (zh) * 2010-11-10 2013-03-27 中国农业科学院上海兽医研究所 猪瘟合成肽疫苗及其应用
WO2014063832A1 (en) 2012-10-28 2014-05-01 Bavarian Nordig A/S Pr13.5 promoter for robust t-cell and antibody responses
US20190307879A1 (en) * 2015-12-04 2019-10-10 The Texas A&M University System Adenovirus-vectored multivalent vaccine

Also Published As

Publication number Publication date
EP3852798A2 (en) 2021-07-28
KR20210065128A (ko) 2021-06-03
PH12021550580A1 (en) 2021-11-29
CN110904127B (zh) 2024-09-20
AU2019345214A1 (en) 2021-04-08
JP2022500050A (ja) 2022-01-04
WO2020060403A2 (en) 2020-03-26
BR112021005079A2 (pt) 2021-06-08
TW202033538A (zh) 2020-09-16
JP7548902B2 (ja) 2024-09-10
WO2020060403A3 (en) 2020-05-14
MX2021003175A (es) 2021-05-14
CA3112800A1 (en) 2020-03-26
CO2021004188A2 (es) 2021-05-20
US20220047694A1 (en) 2022-02-17
ZA202101615B (en) 2023-04-26
CN110904127A (zh) 2020-03-24
TWI777093B (zh) 2022-09-11

Similar Documents

Publication Publication Date Title
CL2021000636A1 (es) Vacuna contra el virus de la peste porcina africana
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
MX2021015465A (es) Vacuna para fiebre porcina africana.
CO2017007105A2 (es) Nuevos virus de tilapia
BR112013020070A8 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
EA201590597A1 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
AR110632A1 (es) Vectores del adenovirus canino
RU2015135890A (ru) Композиция вакцины
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
BR112016023688A2 (pt) célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada
MX2022007398A (es) Vacunas contra el virus de la fiebre porcina africana y métodos para usarlas.
HRP20240163T1 (hr) Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
MX2023000041A (es) Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
CO2023014970A2 (es) Vacuna contra el coronavirus que comprende una proteina mosaico
MX2020006937A (es) Inmunógenos peptídicos y formulaciones de estos dirigidos a la ige unida a la membrana para el tratamiento de enfermedades alérgicas mediadas por ige.
WO2019139648A3 (en) Dna antibody constructs for use against ebola virus
AR125310A1 (es) Vacuna contra el coronavirus que comprende una proteína mosaico
Lazarte Enhancement of immunogenicity in glycoprotein-based DNA vaccine by the addition of DDx41, a molecular adjuvant
BR112015022375A2 (pt) imunógenos isolados de proteínas f de rsv, composição imunogênica compreendendo os referidos imunógenos, seus usos e kit
AR104231A1 (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer